- For Patients
- Introduction to the Marshall Protocol
- Length of the MP
- Immunopathology
- Managing immunopathology
- Food and drink
- Light restriction
- Vitamin D metabolite calculator - get feedback on vitamin D results
- Therapeutic probe - best method for determining MP suitability
- Starting the Marshall Protocol
- Resources for patients
- Marshall Protocol summary
- Palliative vs. curative treatments
- Patient interviews on Bacteriality
- Non-MP treatments
- Glossary
- The Protocol
- Marshall Protocol summary
- Publications and presentations
- Science behind immunopathology
- Science behind olmesartan (Benicar)
- Safety of olmesartan
- Resources for physicians
- Vitamin D metabolite calculator - get feedback on vitamin D results
- Therapeutic probe - best method for determining MP suitability
- Physicians' concerns about the MP
- Notice for emergency medical personnel
- The Pathogenesis
- Publications and presentations
- Science behind Marshall Pathogenesis
- Microbes in the human body
- Successive infection and variability in disease
- Autoimmune theory of disease
- Science behind vitamin D
- Metabolism of vitamin D and the VDR
- Th1 Spectrum Disorder - how chronic inflammatory diseases are related
- Transmission of bacteria and onset of chronic disease
- Evolutionary perspective on disease
- Incidence and prevalence of disease
- Evidence that chronic disease is caused by pathogens
- Diseases
- Foundation
- Related Sites
Differences
This shows you the differences between two versions of the page.
| Both sides previous revisionPrevious revisionNext revision | Previous revisionNext revisionBoth sides next revision | ||
| home:special:hospitals_emergencies [09.17.2017] – [If hospitalized] + telmisartan should never be taken by someone in a hospital setting, it will render the patient vulnerable to increased infection sallieq | home:special:hospitals_emergencies [10.19.2018] – [Notes and comments] sallieq | ||
|---|---|---|---|
| Line 93: | Line 93: | ||
| * Patients on the MP should not take **nimesulide** (Aulin / Mesulid / Nimed). It could possibly cause internal bleeding. | * Patients on the MP should not take **nimesulide** (Aulin / Mesulid / Nimed). It could possibly cause internal bleeding. | ||
| * rivaroxaban (Xarelto) increases the risk of bleeding and can cause serious or fatal bleeding. **A specific antidote for rivaroxaban is not available**. | * rivaroxaban (Xarelto) increases the risk of bleeding and can cause serious or fatal bleeding. **A specific antidote for rivaroxaban is not available**. | ||
| - | * telmisartan should never be taken by someone in a hospital setting, it will render the patient vulnerable to increased | + | * telmisartan should never be taken by someone in a hospital setting, it will render the patient |
| * Refuse all antifungals. Refuse all vitamin D supplementation in food, IV fluids or tube feedings. | * Refuse all antifungals. Refuse all vitamin D supplementation in food, IV fluids or tube feedings. | ||
| * Alert staff to any other food allergies. | * Alert staff to any other food allergies. | ||
| Line 135: | Line 135: | ||
| * [[home: | * [[home: | ||
| + | {{tag> | ||
| ===== Notes and comments ===== | ===== Notes and comments ===== | ||
| Line 145: | Line 145: | ||
| * http:// | * http:// | ||
| * http:// | * http:// | ||
| + | |||
| + | |||
| + | ===== References ===== | ||
home/special/hospitals_emergencies.txt · Last modified: 09.14.2022 by 127.0.0.1
© 2015, Autoimmunity Research Foundation. All Rights Reserved.